for a Brighter Tomorrow

JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed Initiates Phase 3 Trial of Oral Insulin

November 24th, 2020|Comments Off on Oramed Initiates Phase 3 Trial of Oral Insulin

NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) [...]

Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020

November 12th, 2020|Comments Off on Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: [...]